Image Credit: Canva (representational purpose only)
Mysterious Fog in the US , Canada and UK: A dense, eerie fog with a "burning chemical-like smell" has spooked a good part of North America and parts of the United Kingdom and Canada. With social media amplifying all concerns, this phenomenon has sparked attention across all social media platforms. However, at the heart of this mysterious fog are a conjunction of natural events, social psychology, and environmental conditions that culminated in all the conspiracy theories and public health fears. Here's a closer look at the mysterious fog, its potential causes, and the societal response it has triggered.
The first reports of this "mysterious fog" came in from Florida where a resident said that they experienced respiratory symptoms, feverish warmth, and stomach cramps after contact with the fog. Similar stories started flooding social media, and within a day or two, a sinister force seemed to sweep across the United States, Canada, and parts of the UK. From Texas to Minnesota, people reported weird odors and health issues that they thought were linked to this bizarre atmospheric event.
Some witnesses were said to see "white particles" swirling through the air; theories ranged from a chemical attack or experimental weapon to drone-related chemical dispersals and references to historical military experiments, such as the infamous 1950s "Operation Sea-Spray."
Fuel to the fire were added when videos and posts, hundreds of thousands in number, began circulating on social media sites like TikTok and X (formerly Twitter) speculating on the origin of the fog. Hashtags like #ToxicFog went trending for days. Hysteria created a self-reinforcing loop in which every post spurred further scrutiny and fear.
Fog is essentially a low-lying cloud formed when the air temperature cools to its dew point, causing water vapor to condense into tiny droplets or ice crystals. Several types of fog—advection fog, radiation fog, and valley fog—can form depending on conditions such as warm, moist air moving over cooler land or when temperatures plummet rapidly under clear skies.
Such chemical-like smell as reported during the occurrence of fog events is sometimes attributed to air pollution. It acts like a sponge, where it absorbs these pollutants, which include sulfur dioxide and nitrogen oxides, among others, that emit from industries. This mixture, therefore, leads to a stench that could be mistaken as unnatural or even toxic.
Also Read: Health Concerns Rise As US, Canada, and UK Come Under The Blanket Of Thick, Dense, Toxic Fog
High moisture levels from fog can significantly exacerbate symptoms related to respiration, but especially in already predisposed asthmatics and allergy patients. The connection of these symptoms with actual fever, stomach cramps, and puffy eyes is too remote. Experts assume that the irritating effects of entrapped pollutants trapped in fog tend to affect more the eyes and throat rather than the rest of the body affected by some report.
Social media amplified a natural weather event into a health epidemic. It made the personal experience of individuals become a cause for fear and speculation, a domino effect.
According to psychologists, this is a concept of selective perception, wherein once people's attention is drawn to environmental anomalies, they begin to notice them. This mirrors earlier panics, such as the Seattle windshield pitting panic of 1954. Then, atomic bomb testing caused fear in many and started to have people looking at their windshields for small marks that they had not seen before. Likewise, postings on the strangeness of the fog probably increased public awareness and suspicion, with people looking to attach unrelated symptoms to the phenomenon.
The fog hysteria shares a commonality with other instances of mass panic, such as the "drone sightings" of recent years or the Cold War-era fears of biological warfare.
Also Read: Mysterious Fog Is Making Americans Sick
These events underscore how fear can cloud judgment, especially when amplified by social media and sensationalist headlines. While historical cases, such as "Operation Sea-Spray," offer concrete evidence of the existence of unethical experiments, the jump from a natural weather condition to theories of chemical attacks exemplifies a more modern trend of connecting unrelated dots, all wonderfully seeded in distrust and anxiety.
Despite the swirling rumors, meteorologists and scientists are in agreement that the mysterious fog is not as alarming as it seems. It is well known that fog traps and amplifies pollutants, especially in urban and industrial regions. Moreover, winter months are the most conducive for fog formation, so its recent prevalence is unsurprising.
On the other hand, environmentalists advise that the fog should wake everyone up to increased levels of pollution. The reported odors and health irritations could be just symptoms of far deeper systemic issues like industrial emissions and lack of control over air quality.
The authorities must be transparent in their communication to combat misinformation and allay public fears. Governments and environmental agencies must provide timely updates on weather phenomena, air quality, and health risks. Initiatives like real-time pollutant tracking and public education campaigns can help demystify natural occurrences while addressing valid environmental concerns.
The mysterious Canada fog is a compelling case study in how environmental events intersect with psychology and societal dynamics. While rooted in natural phenomena, the fog became a vessel for collective fears, amplified by modern technology and historical anxieties.
In this information era where communication occurs at an almost lightning pace, the fog becomes a metaphor that reminds everyone about scientific literacy, environmental responsibility, and an effective balance when considering public concern. Whether perceived as a marvel of nature or as a tale that serves to teach, it left a very powerful mark in people's minds.
Credit: iStock
Stopping GLP-1 drugs such as Ozempic, Wegovy, Mounjaro and Zepbound may cause some of their cardiovascular benefits to fade, a large new study suggests.
Researchers from Washington University in St. Louis found that people who stopped GLP-1 treatment had a progressively higher risk of major cardiovascular events, including heart attack, stroke and death. After two years off treatment, their risk was 22% higher than among those who continued taking the drugs.
The findings, published in BMJ Medicine, are significant as GLP-1 drugs are widely used to treat type 2 diabetes and obesity and have also been shown to provide cardiovascular benefits.
Researchers analyzed health data from 333,687 US veterans with type 2 diabetes over up to three years. Of these, 132,551 had been prescribed GLP-1 drugs, while 201,136 had been prescribed sulfonylureas, another class of diabetes medicines.
Treatment status was reassessed every six months. About 26% of GLP-1 users stopped treatment completely, while another 23% had a treatment gap of at least six months before restarting.
The longer people remained off treatment, the greater their cardiovascular risk.
After one year without restarting, the risk of major cardiovascular events was 14% higher than among continuous users. After two years, it was 22% higher.
"There is enormous exuberance about starting GLP-1 drugs, but not nearly enough attention to what happens when people stop," said senior author Ziyad Al-Aly, a clinical epidemiologist at Washington University.
Also read: Are GLP-1 Drugs Safe for Children? Study Finds Nutritional Deficiency in Nearly 17% Within a Year
People who remained on GLP-1 drugs throughout the three-year study had an 18% lower risk of major cardiovascular events than those taking sulfonylureas.
That translated to about four fewer major cardiovascular events per 100 people over three years.
Those who remained on treatment for two or 2.5 years before stopping also had lower cardiovascular risk, by 7% and 15%, respectively.
However, people who stopped before 18 months did not have a significant reduction in cardiovascular risk compared with those taking sulfonylureas by the end of the study.
Interrupting GLP-1 treatment and later restarting it was associated with less cardiovascular protection. While continuous users had an 18% reduction in major cardiovascular events, those who stopped and later restarted had an average 12% reduction.
Even a six-month treatment gap was associated with a 4% to 8% increase in cardiovascular risk compared with continuous use.
Al-Aly said many patients stop GLP-1 drugs because of "cost, side effects or shortages."
"When they stop, it's not just weight that comes back; they experience a resurgence in inflammation, blood pressure, and cholesterol. Weight regain is visible; the metabolic reversal is not," he said.
"Our data suggest this metabolic whiplash is detrimental to heart health," Al-Aly added.
Read More: EXCLUSIVE: GLP-1 Drugs Are The ‘New Statins’, Says University Hospital Birmingham Professor
Restarting treatment appeared to restore some cardiovascular protection, but not all of it.
The researchers said the findings suggest that cardiovascular benefits gained during GLP-1 treatment may diminish after treatment is interrupted.
"Clinicians should treat adherence to GLP-1 treatment as an important outcome in its own right -- not an afterthought," Al-Aly said.
He added that healthcare systems should help patients manage side effects, address cost barriers and understand that GLP-1 drugs are used to manage chronic conditions.
Credit: AI
The human brain has always been considered to be a single organ. But according to Stanford Medicine researchers, the brain's growth history indicates that it originates from two different populations of early cells that follow separate developmental paths.
The findings, published in Nature Neuroscience, suggest that the front and back parts of the brain develop from different types of progenitor cells, questioning the long-believed idea that the entire brain originates from one common cell.
An important point to note is that this does not mean that humans have two completely separate brains. The two developmental systems ultimately fuse together and function as one brain.
During early development, cells called progenitor cells enable the production of specialised brain cells, including neurons. Researchers found that the cells that form the forebrain and midbrain follow a different developmental pathway from those that form the hindbrain, which includes the brainstem.
The forebrain is involved in neurological functions like language, consciousness and higher-level thinking. The hindbrain contains structures that control essential functions including breathing, heartbeat, sleep and swallowing.
Kyle Loh, associate professor of developmental biology at Stanford Medicine and senior author, said, “We’ve shown for the first time that the front of the brain arises from a totally different progenitor cell than the back of the brain.”
He added, “Our discovery means that we can now grow neurons from the back of the brain, the hindbrain, in a petri dish and study their functions.”
Also read: Is Controlling BP Enough After a Brain Bleed? Doctors Explain How to Prevent Another Stroke
Scientists have been able to grow several types of human brain cells in the laboratory, but creating hindbrain neurons has been challenging.
The new findings give some clarity about why some previous approaches were unsuccessful. Researchers were attempting to transform forebrain or midbrain progenitor cells into hindbrain cells, but the Stanford team found that these cells are fundamentally different from the beginning of development.
Jokhai, one of the researchers involved in the study, explained, “Previous attempts to make hindbrain neurons likely tried to coax forebrain and midbrain progenitors into hindbrain cells, which our study shows is not possible.”
He added, “In stem cell biology, people are always fixated with creating the end cell type, like the neuron. But it’s important to begin at the earliest stages of embryonic development.”
The discovery could have various practical implications for neurological research. The hindbrain and brainstem contain neurons involved in breathing, swallowing and movement, meaning researchers need reliable human cells to study diseases that damage these systems.
Stanford scientists say the new findings allowed them to understand and generate functional human hindbrain neurons in the laboratory. This could provide new models for studying conditions like amyotrophic lateral sclerosis (ALS) and spinal muscular atrophy (SMA).
Instead of studying these diseases only in animals or using cells that do not accurately represent the affected brain region, researchers may now be able to grow relevant human neurons and investigate how they develop, malfunction and respond to different treatments.
The finding could therefore change not just how scientists understand the human brain's anatomy, but how they understand its origins and how they recreate different brain regions in the laboratory.
Credit: iStock
As artificial intelligence (AI) rapidly reshapes health research and clinical care, Anthropic and medical knowledge platform OpenEvidence have announced a collaboration to provide AI-powered clinical decision support to healthcare providers in dozens of low- and middle-income countries.
OpenEvidence answers doctors’ clinical questions using peer-reviewed research and treatment guidelines. The platform, already free to clinicians in the US and Europe, will now be extended to providers in countries where access to medical literature, specialist expertise and continuing education may be limited.
The initiative is being rolled out in about 100 countries, including Uganda, Angola, Sudan, Haiti and Mongolia, according to a list provided by OpenEvidence.
“Access to medical knowledge shouldn’t depend on geography,” OpenEvidence founder Daniel Nadler said.
Also read: Anthropic Says Claude Blocked Bird Flu, Chikungunya Research: How AI Could Enable Biological Misuse
Rajeev Jayadevan, former president of IMA Cochin and convener of the Research Cell, Kerala, told HealthandMe that doctors in Western countries already have access to OpenEvidence, which has also been incorporated into electronic medical records at major US hospitals.
He said the platform could help doctors quickly access medical evidence at the point of care.
“The advantage is that the doctor will have instant access to relevant research papers published in multiple journals, all at once, while asking a specific question about a patient while at the bedside,” Dr Rajeev said.
He called it “a major time-saving step for the busy clinician, who may not have the time to go to the library, sit down with medical journals or textbooks, or even do internet-based searches to look for relevant papers”.
Dr Rajeev also said wider access to medical information could help reduce inequalities in healthcare.
“Medical information that directly helps patients must be available to the doctor free of charge,” he said.
However, AI-based clinical tools also have limitations, particularly when used across different healthcare systems.
“Potential disadvantages include the need for doctors to be trained in digital health literacy and the fact that the answer provided by AI algorithms heavily depends on what the doctor asked for, and in what format,” Dr Rajeev said.
“Some of these issues can be ironed out by using templates, so that important information or keywords are not missed by the doctor who enters the query. Other risks include relying on data from other countries and treatment options that are unavailable or expensive for the local community,” he added.
The expansion of AI in healthcare comes as the WHO has separately called for stronger ethics oversight of AI-related health research.
In a report published this week, WHO warned that rapid advances in AI are creating challenges around privacy, bias, fairness, transparency and accountability. It said existing research ethics systems may need additional expertise to assess risks associated with AI and large datasets.
Dr Rajeev said AI-driven research, particularly when it involves large datasets crossing national borders, may require ethics committees to include experts in computer science, data ethics and bioinformatics.
“Ethics Committees by themselves will need to be upgraded to incorporate computer scientists, data ethicists, and bioinformaticians.”
WHO also said oversight should extend beyond ethics committees to researchers, funders, scientific journals, data governance bodies, professional societies and regulators.
For low- and middle-income countries, clinical AI could help bridge gaps in access to medical literature and specialist knowledge. At the same time, WHO has highlighted the need for local capacity and safeguards to ensure that AI systems developed largely in higher-income settings are appropriate for different healthcare systems and do not introduce new inequities.
Dr. Rajendra Pratap Gupta, chairman, Health Parliament and co-chair, Global Policy Network on AI, UN Internet Governance Forum told HeathandMe that accountability is key when it comes to AI in healthcare.
“Anthropic’s partnership with OpenEvidence shows that clinical AI is moving rapidly from experimentation to global deployment. WHO’s warning reminds us that innovation cannot outrun ethics. In my view, accountability must be the central pillar of AI governance, because when technology influences clinical decisions, responsibility for evidence, safety and patient outcomes must never become blurred,” added the expert.
© $2026 Times Horizon Private Limited